Current stock page

Financial Data

PTCT Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Sep 4, 2026

PTCT

Financial Data
PTC Therapeutics, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 6/10
Low Priority
Above Peers
Score data as of Sep 4, 2026
Last price
$69.30
-$2.10 (-2.94%)
Latest market quote
Momentum33
Value38
Quality82
Risk Resilience61
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 6, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$360.52M$272.55M$164.68M$211.01M$178.88M$1.18B$213.17M$196.79M
Gross Profit$340.6M$244.52M$148.38M$95.07M$167.46M$1.16B$196.89M$185.94M
Operating Income
Net Income$83.5M-$2.81M-$134.97M$15.9M-$64.85M$866.56M-$65.89M-$106.65M
EPS$1.01-$0.03-$1.67$0.2-$0.83$11.09-$0.85-$1.39
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$129.11M-$59.04M-$34.27M-$66.3M-$58.33M$870.1M-$30M-$76.99M
Capital Expenditure-$7.14M-$1.35M-$37.29M-$3.45M-$3.99M-$2.53M-$6.5M-$10.78M
Free Cash Flow$121.97M-$60.4M-$71.56M-$69.75M-$62.33M$867.57M-$36.5M-$87.77M
Net Cash Provided By Operating Activities$129.11M-$59.04M-$34.27M-$66.3M-$58.33M$870.1M-$30M-$76.99M
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$3.25B$2.87B$2.9B$2.64B$2.63B$2.66B$1.71B$1.84B
Total Debt$696.47M$395.09M$2.71B$2.49B$388.17M$389.62M$2.47B$400.21M
Cash And Cash Equivalents
Total Liabilities$3.42B$3.05B$3.1B$2.8B$2.84B$2.84B$2.8B$2.9B
Total Stockholders Equity-$165.36M-$180.47M-$205.31M-$155.76M-$206.55M-$185.76M-$1.1B-$1.05B
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio20.19-567.75-11.3778.66-14.711.15-13.22-6.69
P/B ratio-40.95-31.15-29.85-32.11-18.48-21.43-3.17-2.71
P/S ratio18.7820.6337.2223.721.343.3816.3514.5
Debt To Equity-4.21-2.19-13.19-16-1.88-2.1-2.25-0.38
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio-40.95-31.15-29.85-32.11-18.48-21.43-3.17-2.71
P/S ratio18.7820.6337.2223.721.343.3816.3514.5
Return On Equity-50.49%1.56%65.74%-10.21%31.40%-4.66%6.00%10.12%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-144
multipleSep 4, 2026
Pb
-35.42
multipleSep 4, 2026
Revenue Growth Yoy
32.28
percentSep 4, 2026
EPS Growth Yoy
3,466.67
percentSep 4, 2026
Gross Margin
82.14
percentSep 4, 2026
Operating Margin
11.52
percentSep 4, 2026
ROE
21.72
percentSep 4, 2026
ROIC
2.61
percentSep 4, 2026
Debt To Equity
-4.21
ratioSep 4, 2026
FCF Yield
-5.65
percentSep 4, 2026
Technical indicators
Close
69.3
priceSep 4, 2026
Volume
673,539
volumeSep 4, 2026
Rsi14
39.75
indexSep 4, 2026
MACD
-1.13
indexSep 4, 2026
MACD Signal
-1.2
indexSep 4, 2026
MACD Histogram
0.07
indexSep 4, 2026
Adx14
18.61
indexSep 4, 2026
Sma50
75.82
priceSep 4, 2026
Sma200
73.35
priceSep 4, 2026
Atr14
2.32
priceSep 4, 2026
Historical Volatility
0.3
percentSep 4, 2026
Volume Ma20
789,713.95
volumeSep 4, 2026
Risk measures
Resilience Score
61
score_0_100Sep 4, 2026
Beta
0.55
ratioSep 4, 2026
Volatility Annual
40.39
percentSep 4, 2026
Max Drawdown
-27.17
percentSep 4, 2026
Sharpe Ratio
0.55
ratioSep 4, 2026
Var95
-3.67
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PTCT Financial Data FAQ

What is PTC Therapeutics, Inc.'s revenue?

PTC Therapeutics, Inc.'s revenue is one of the core financial data points for PTCT. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is PTC Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether PTC Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PTCT's EPS?

PTCT's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is PTC Therapeutics, Inc.'s net income?

PTC Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does PTC Therapeutics, Inc. generate?

Free cash flow shows how much cash PTC Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does PTC Therapeutics, Inc. have?

Cash and debt help frame PTCT's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.